Guidance

HPE: definition, screening, diagnosis, treatment

This leaflet sets out alobar holoprosencephaly (HPE) and the processes following a suspected or confirmed diagnosis of the condition.

• From: Public Health England
• Published: 1 July 2009
• Last updated: 27 April 2020 — See all updates

This publication was withdrawn on 27 April 2020

This has been withdrawn as alobar holoprosencephaly is not a condition screened for by the fetal anomaly screening programme.

More information is available at: Fetal anomalies: screening, conditions, diagnosis, treatment.

Documents

Alobar holoprosencephaly (HPE) information for health professionals

PDF, 697 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This publication sets out information on the fetal anomaly alobar holoprosencephaly (HPE).

The document includes:

• definition of the condition
• screening and diagnosis procedure
• prevalence of the condition
• treatment for the disease
• likely outcome for the baby
• prevention processes
• the referral pathway

Published 1 July 2009
Last updated 27 April 2020 + show all updates

1. 27 April 2020

   Publication withdrawn as Alobar holoprosencephaly is not a condition screened for by the fetal anomaly screening programme.

2. 1 July 2009

   First published.